- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
- No Questions Asked: FDA’s Psychedelics Public Hearing
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Approvals to Access: A Crude Schematic
- Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
- Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
- Pα+ Library: Psychedelic REMS
- Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?
- A Closer Look at Definium’s Phase 3 LSD for GAD Readout
- Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet
- Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI
- Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
- Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development
MAPS Podcast
- Field Notes #5: ‘Psychedelics Week’ in Washington D.C.
- ‘Move Fast, with Precision’: Notes from ARPA-H’s Ibogaine Workshop
- Pα+ Psychedelic Bulletin #231: Compass Shares 52 Week Follow-Up, Training Grant Recipients; Xylo Enters the Clinic; RFK Jr. Hosts Hubbard
- No Questions Asked: FDA’s Psychedelics Public Hearing
- Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Approvals to Access: A Crude Schematic
- Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM
- Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD
- Pα+ Library: Psychedelic REMS
- Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?
- A Closer Look at Definium’s Phase 3 LSD for GAD Readout
- Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet
- Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI
- Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
- Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development